XML 36 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration Agreements (Tables)
6 Months Ended
Jun. 28, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Revenues Under Collaboration Agreement Such royalties accruing to GSK were as follows (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Royalties accruing to GSK
$
7,833

 
$
5,628

 
$
15,115

 
$
10,753


Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Ipsen collaboration revenues
$
22,249

 
$
34,043

 
$
44,117

 
$
87,852


Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Daiichi Sankyo collaboration revenues
$
20,114

 
$

 
$
20,114

 
$
20,000


Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Profits on U.S. commercialization
$
1,349

 
$
2,696

 
$
2,404

 
$
4,069

Royalty revenues on ex-U.S. sales
$
1,323

 
$
1,546

 
$
2,813

 
$
2,895


Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2019
 
2018
 
2019
 
2018
Takeda collaboration revenues
$
1,565

 
$
1,986

 
$
13,058

 
$
4,903